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Abstract
Objectives: To identify risk factors for severe disease and death among patients with diabetes and coronavirus disease
2019 (COVID-19) infection.
Methods: This retrospective cohort study conducted at three hospitals included 733 consecutive patients with DM
admitted with conﬁrmed COVID-19 (March 1 - December 31, 2020). Multivariable logistic regression was performed to
identify predictors of severe disease and death.
Results: The mean age was 67.4 ± 14.3 years, 46.9% were males and 61.5% were African American. Among all patients,
116 (15.8%) died in the hospital. A total of 317 (43.2%) patients developed severe disease, 183 (25%) were admitted to an
ICU and 118 (16.1%) required invasive mechanical ventilation. Increasing BMI (OR, 1.13; 95% CI, 1.02e1.25), history of
chronic lung disease (OR, 1.49; 95% CI, 1.05e2.10) and increasing time since the last HbA1c test (OR, 1.25; 95% CI,
1.05e1.49) were the preadmission factors associated with increased odds of severe disease. Preadmission use of metformin (OR, 0.67; 95% CI, 0.47e0.95) or GLP-1 agonists (OR, 0.49; 95% CI, 0.27e0.87) was associated with decreased odds
of severe disease. Increasing age (OR, 1.21; 95% CI, 1.09e1.34), co-existing chronic kidney disease greater than stage 3
(OR, 3.38; 95% CI, 1.67e6.84), ICU admission (OR, 2.93; 95% CI, 1.28e6.69) and use of invasive mechanical ventilation
(OR, 8.67, 95% CI, 3.88e19.39) were independently associated with greater odds of in-hospital death.
Conclusion: Several clinical characteristics were identiﬁed to be predictive of severe disease and in-hospital death
among patients with underlying diabetes hospitalized with COVID-19.
Keywords: COVID-19, SARS-CoV-2, Diabetes, Mortality, Glucose

1. Introduction

S

evere acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19), the disease that emerged in
late 2019 in China. Its primary clinical feature is an
acute pneumonic process with hypoxemic respiratory
failure. As of June 2022, more than 542 million cases
and 6.3 million deaths worldwide have occurred.1
Early into the COVID-19 pandemic, diabetes was
identiﬁed as a major comorbidity associated with
severe illness and mortality in hospitalized patients.
According to the available published literature, the

worldwide prevalence of diabetes among patients
hospitalized with COVID-19 ranged from 4.7% up to
44%.2 Furthermore, preexisting diabetes has been
associated with a 20% increase in the odds of inhospital mortality, based on the data from a retrospective cohort study3 of 64,781 patients treated in
592 US hospitals.
A growing body of literature has identiﬁed that
poor glycemic control was associated with worse
COVID-19 outcomes. Studies4,5 have shown that
poorly controlled diabetes prior to the admission for
COVID-19 was associated with worse outcomes.
Additionally, reports6,7 have revealed that poor
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inpatient glycemic control during COVID-19related hospital stay was associated with poor outcomes as well. As yet, few studies have taken into
account combined effects of both preadmission and
glycemic control during hospitalization. As the
pandemic continues, and with the emergence of
multiple variants associated with enhanced transmissibility and increased virulence,8 it remains
important to understand how underlying diabetes
affects COVID-19-related outcomes.
Therefore, this study aims to examine the diabetes-speciﬁc risk factors for severe disease and
death. Furthermore, the goal was to evaluate both
preadmission and inpatient glycemic control and its
effect on hospital outcomes.

2. Methods
2.1. Study design and participants
This retrospective, observational, cohort, multisite
study was conducted at three hospitals within one
health care system. These hospitals, with a total of
875 beds, provide acute, primary and specialty care
services to residents in various communities. This
study was approved by the health care system
Institutional Review Board.
All adult non-obstetric patients with diabetes
consecutively admitted with a conﬁrmed COVID-19
infection between March 1 and December 31, 2020
were included. A COVID-19 infection was deﬁned by
a positive qualitative polymerase-chain-reaction
assay or antigen test. Diagnosis of diabetes was
deﬁned by using ICD-10 code in the electronic medical
record (EMR), hemoglobin A1c (HbA1c) greater than
6.5% (47.5 mmol/mol) within 12 months prior to or
during the hospitalization, and/or ongoing use of any
anti-diabetic agents prior to the admission.
Participants were excluded from this analysis if
they had had a positive test more than 14 days prior
to admission, as our idea was to focus on the acute
illness. For better glycemic control assessment, we
excluded patients with fewer than three glucose
measurements during the hospitalization. Patients
who were transferred between hospitals within the
health system were treated as one hospital
encounter. For patients who were discharged and
subsequently readmitted, their data from both
admission time frames were used, provided that
inclusion and exclusion criteria had still been met.
2.2. Data collection
Data were extracted from EMR and included demographic information, diabetes history, comorbid

conditions, laboratory results, level of oxygen supplementation, in-hospital diabetes, and COVID-19
treatments. The most recent HbA1c level prior to
the discharge date was obtained from EMR. Time
since HbA1c was deﬁned as the difference between
the HbA1c test date and the hospital discharge date.
The outpatient diabetes treatment regimen was
collected
from
the
admission
medication
reconciliation.
All blood glucose levels, by laboratory serum
measurement or by point-of-care testing, were
collected for the entire duration of hospital stay. For
each patient, the mean glucose level and standard
deviation were calculated. Target glucose was
deﬁned as glucose level within the range of
70e180 mg/dL. The percentage of glucose readings
in the target range was derived from the following
formula: ([number of glucose readings within the
target range per patient]/[total number of glucose
readings per patient]). Glycemic variability (GV)
was expressed as the percentage coefﬁcient of
variation for glucose (CV), derived from the
following formula: ([SD of glucose]/[mean glucose])
x 100. Severe hypoglycemia was deﬁned as at least
one value less than 54 mg/dL (measured by laboratory measurement only). Severe hyperglycemia
was deﬁned as at least one value greater than
400 mg/dL.
Outcome measures included severe disease and
in-hospital death. Diagnosis of severe disease was
based on the WHO COVID-19 clinical progression
scale9 and included scores 6 to 10 (need for high
ﬂow nasal cannula, noninvasive positive pressure
ventilation, mechanical ventilation and death). A
score of 10 represented death and was used as
another outcome variable.
2.3. Statistical analysis
Standard descriptive analyses were provided using
mean values and standard deviations for continuous
variables or frequency counts and percentages for
categorical variables. If there was strong evidence of
non-normality for any of the continuous variables,
based on the KolmogoroveSmirnov test and QeQ
plots, then the median and interquartile range
(IQR) were reported.
We imputed missing values using multivariate
imputation by chained equations (MICE) with predictive mean matching (MICE, R package, version
3.13.0).10 A total of 10 datasets were imputed. All
regression analyses were performed in each
imputed dataset and model parameters were
pooled. To identify predictors of severe disease, we
performed multivariable logistic regression with
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preadmission characteristics as covariates. Candidate variables for the in-hospital mortality model
included both preadmission and data from the
hospitalization. Given few events relative to the
number of variables of interest, to protect against
overﬁtting, variable selection was warranted. Elastic
net regression was used to identify the important
features affecting the mortality of the cohort
(glmnet, R package, version 4.1-2).11 We used 10fold repeated cross-validation to train and tune our
model on 80% of the sample. The model was then
applied to the rest of the sample. Terms with nonzero coefﬁcients in at least 50% of imputed datasets
were included in the ﬁnal model.12 To investigate
the potential inﬂuence of glycemic control metrics
on mortality, we ﬁtted another logistic regression
model with the addition of CV and percentage in the
target range as covariates.
Two-sided P values < 0.05 were considered statistically signiﬁcant. All statistical analyses were
performed using the R statistical software, version
4.1.0 (R Foundation for Statistical Computing).13

The total number of glucose values for the study
population was 41,614. Of those, 8217 (19.7%) were
performed through standard laboratory blood
draws and 33,397 (80.3%) were obtained with pointof-care devices. The median (IQR) number of
glucose testing per patient per day was 5.1 (4.6e5.9).

3. Results

Table 4 shows unadjusted and adjusted odds of
in-hospital mortality. In the adjusted analysis, variables independently associated with higher in-hospital mortality were increasing age (OR, 1.21; 95%
CI, 1.09e1.34), history of CKD greater than stage 3
(OR, 3.38; 95% CI, 1.67e6.84), ICU admission (OR,
2.93; 95% CI, 1.28e6.69) and the use of invasive
mechanical ventilation (OR, 8.67, 95% CI,
3.88e19.39).
In the univariate analysis, a CV greater than 36%
was associated with higher odds of in-hospital death
(OR, 1.56; 95% CI, 1.04e2.34) and having more than
50% of the BG values in the target range was associated with decreased odds of in-hospital death (OR,
0.62; 95% CI, 0.40e0.93). However, after controlling
for other covariates, these terms were not independently predictive of in-hospital mortality (model 2).

3.1. Study participants
There were 774 COVID-19-related hospital admissions to the three hospitals during the study
period that met the inclusion criteria. After
excluding patients with repeated admissions (26
admissions), fewer than three glucose measurements during the hospitalization (8 patients), and
more than 14 days between the initial COVID-19
test and admit date (7 patients), the ﬁnal study
cohort consisted of 733 patients.
The majority of patients had type 2 diabetes (726
[99%]). The mean age ±SD was 67.4 ± 14.3, 344
(46.9%) were males and 451 (61.5%) patients were
African American. Hypertension was the most
common comorbidity (662 [90.3%]). Metformin was
the most widely prescribed antidiabetic medication
(377 [51.4%]), followed by insulin (313 [42.7%]).
Table 1 shows preadmission clinical characteristics
by peak disease severity.
Table 2 shows laboratory values, COVID-19 and
DM management by disease severity. A total of 183
(25%) patients were admitted to an ICU and 118
(16.1%) required invasive mechanical ventilation. A
total of 317 (43.2%) patients developed severe disease, of which 201 (27.4%) survived and 116 (15.8%)
died. Median (IQR) in-hospital length of stay for the
cohort was 8 (5e13) days. Among inpatients with an
ICU admission, median (IQR) in-hospital length of
stay was 12 (6e21) days.

3.2. Preadmission risk factors for severe disease
Table 3 shows the unadjusted and adjusted odds
of severe disease. In the adjusted analysis,
increasing BMI (OR, 1.13; 95% CI, 1.02e1.25), history
of COPD (OR, 1.49; 95% CI, 1.05e2.10) and
increasing time since the last available HbA1c result
(OR, 1.25; 95% CI, 1.05e1.49) were independently
associated with increased odds of severe disease. On
the other hand, preadmission use of metformin (OR,
0.67; 95% CI, 0.47e0.95) and GLP-1 agonists (OR,
0.49; 95% CI, 0.27e0.87) was associated with lower
odds of severe disease.
3.3. Risk factors for in-hospital death

4. Discussion
This study examined the characteristics and clinical outcomes of a cohort of patients with diabetes
admitted with COVID-19. A total of 43.2% of patients developed severe disease and 15.8% died
during the hospital stay. Our objective was to
identify factors associated with severe disease and
death.
Major comorbidities that were associated with
increased odds of severe disease were obesity and
chronic lung disease. Bello-Chavolla et al.14 have
previously observed that obese patients had higher
rates of hospitalization and mortality with COVID-19.
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Table 1. Preadmission clinical characteristics of patients with diabetes hospitalized with COVID-19, overall and by peak disease severity.
Characteristic

All patients
(n ¼ 733)

Demographic data
Mean age, years
67.4 ± 14.3
Male sex, n (%)
344 (46.9)
African American, n (%)
451 (61.5)
Ever smoker, n (%)
146 (19.9)
Mean BMI, kg/m2
32.3 ± 8.3
Comorbidities, n (%)
Hypertension
662 (90.3)
Hyperlipidemia
578 (78.9)
CADc
226 (30.8)
CKD stage 3 or higher
136 (18.6)
CVA or TIA
125 (17.1)
Chronic lung diseased
214 (29.2)
Diabetes history and outpatient treatment, n (%)
Type 2 diabetes
726 (99.0)
Median HbA1c, %
7.4 (6.6e9.0)
Median HbA1c, mmol/mol
57.4 (48.6e74.9)
Median time since HbA1c, days
80 (9e330)
Insulin
313 (42.7)
Metformin
377 (51.4)
Sulfonylurea
142 (19.4)
Thiazolidinedione
21 (2.9)
DPP-4 inhibitor
70 (9.5)
GLP-1 agonist
65 (8.9)
SGLT2 inhibitor
41 (5.6)
Use of systemic steroidse
60 (8.2)

Missing data,
n (%)

Mild diseasea
(n ¼ 416)

Severe disease,
excluding deathb
(n ¼ 201)

Death
(n ¼ 116)

e
e
e
e
28 (3.8)

66.8 ± 14.2
188 (45.2)
260 (62.5)
76 (18.3)
31.8 ± 8.1

65.6 ± 14.7
101 (50.2)
125 (62.2)
42 (20.9)
33.0 ± 8.2

72.3 ± 13.0
55 (47.4)
66 (56.9)
28 (24.1)
32.6 ± 9.1

e
e
e
e
e
e

376 (90.4)
334 (80.3)
122 (29.3)
64 (15.4)
78 (18.8)
106 (25.5)

177 (88.1)
149 (74.1)
56 (27.9)
29 (14.4)
26 (12.9)
65 (32.3)

109 (94.0)
95 (81.9)
48 (41.4)
43 (37.1)
21 (18.1)
43 (37.1)

e
60 (8.2)
60 (8.2)
60 (8.2)
e
e
e
e
e
e
e
e

413 (99.3)
7.4 (6.6e9.0)
57.4 (48.6e74.9)
75 (6e299)
166 (39.9)
235 (56.5)
84 (20.2)
12 (2.9)
41 (9.9)
44 (10.6)
25 (6.0)
33 (7.9)

199 (99.0)
7.5 (6.6e9.2)
58.5 (48.6e77.1)
75 (10e306)
84 (41.8)
96 (47.8)
36 (17.9)
8 (4.0)
18 (9.0)
17 (8.5)
15 (7.5)
14 (7.0)

114 (98.3)
7.3 (6.5e8.7)
56.3 (47.5e71.6)
130 (25e469)
63 (54.3)
46 (39.7)
22 (19.0)
1 (0.9)
11 (9.5)
4 (3.4)
1 (0.9)
13 (11.2)

Abbreviations: BMI ¼ body mass index; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; CVA ¼ cerebrovascular accident; TIA ¼ transient ischemic attack; HbA1c ¼ hemoglobin A1c; DPP-4 ¼ dipeptidyl peptidase 4; GLP-1 ¼ glucagon-like peptide 1;
SGLT-2 ¼ sodium-glucose cotransporter-2.
Numerical data are expressed as mean ± SD or median (IQR). Categorical data are expressed as n (%).
a
Included patients not on oxygen therapy or patients requiring low ﬂow nasal cannula.
b
Included patients requiring high ﬂow nasal cannula, noninvasive positive pressure ventilation or invasive mechanical ventilation.
c
Included patients with stable angina or history of acute coronary syndrome.
d
Included patients with asthma, chronic obstructive pulmonary disease or pulmonary hypertension.
e
Outpatient use of systemic steroids within 2 weeks prior to the admission.

Furthermore, by using casually ordered mediation
analysis, they showed that obesity mediates 49.5% of
the effects of diabetes on COVID-19 lethality. Obesity
has been shown to decrease the immune response,
decrease lung compliance and impair ventilation,
thus leading to worse outcomes with respiratory infections.15 Similarly, an underlying chronic obstructive pulmonary disease has been shown to increase
the risk of severe pneumonia and poor outcomes with
COVID-19.16
Our data did not show any signiﬁcant association
between hemoglobin A1c values and disease
severity. This is consistent with multiple previous
reports,4,17 including the CORONADO study,18 a
nationwide multicenter observational study done in
France. Interestingly, we found that increasing time
since the last HbA1c test was associated with greater
odds of severe disease. This remained signiﬁcant
even after adjustment for the HbA1c value, age, sex,

comorbidities and diabetes medications. We did not
ﬁnd previous studies reporting similar results. It is
possible to hypothesize that these patients had less
access to health care or less regularity of general
health checks.
In the multivariable analysis, use of metformin or
GLP-1 agonists was associated with decreased odds
of severe disease. Similar results were reported
previously. A recent meta-analysis19 of 17 studies
with a total of 20,719 patients with diabetes found
that metformin was associated with a 36% decrease
in mortality and a 19% decrease in the disease
severity. A recent study20 showed that metformin
attenuated SARS-CoV-2-induced ARDS, by inhibiting NLRP3 inﬂammasome activation and interleukin 1b production in cultured and alveolar
macrophages. Another meta-analysis21 of 9 studies
showed that preadmission use of GLP-1 agonists
was associated with lower mortality in COVID-19,

Table 2. In-hospital clinical characteristics of patients with diabetes hospitalized with COVID-19, overall and by peak disease severity.
Characteristic

COVID-19 disease severity, n (%)
Highest supplemental oxygen required
Nasal cannula
HFNC, NIPPV
IMV
Median duration of the highest oxygen support, days
ICU admission
New VTE during hospital stay
Medications used, n (%)
Dexamethasone
Systemic glucocorticoids other than dexamethasone
Remdesivir
Tocilizumab
Laboratory values
Median admission creatinine, mg/dL
Median admission leukocyte count,  10c cells/mL
Median admission BG, mg/dL
Median glucose CV, %
Median % of BG readings in target range
Severe hypoglycemia, n (%)
Severe hyperglycemia, n (%)
Diabetes management, n (%)
DKA on admission
Insulin drip
Insulin aspart (sliding scale only)
Combination insulinc
New diabetes diagnosis

All patients
(n ¼ 733)

Mild diseasea
(n ¼ 416)

Severe disease,
excluding deathb
(n ¼ 201)

Death
(n ¼ 116)

315 (43.0)
192 (26.2)
118 (16.1)
4 (2e8)
183 (25)
40 (5.5)

308 (74.0)
0 (0)
0 (0)
3 (0e6)
13 (3.1)
15 (3.6)

0 (0)
158 (78.6)
43 (21.4)
5 (3e9)
84 (41.8)
14 (7.0)

7 (6.0)
34 (29.3)
75 (64.7)
5 (2e10)
86 (74.1)
11 (9.5)

362 (49.4)
136 (18.6)
235 (32.1)
50 (6.8)

179 (43.0)
42 (10.1)
104 (25.0)
3 (0.7)

134 (66.7)
53 (26.4)
101 (50.2)
26 (12.9)

49
41
30
21

1.3 (0.9e2.1)
7.0 (5.3e9.3)
170 (121e237)
30.8 (23.0e40.0)
42.9 (24.6e73.4)
38 (5.2)
255 (34.8)

1.2 (0.9e1.9)
6.7 (5.1e9.0)
165 (120e229)
27.9 (21.2e37.9)
49.3 (24.9e85.7)
14 (3.4)
119 (28.6)

1.2 (0.9e2.0)
7.2 (5.5e9.4)
184 (132e239)
32.5 (25.8e41.6)
37.7 (23.7e59.6)
16 (8.0)
85 (42.3)

1.7 (1.2e3.2)
7.6 (5.8e10.0)
170 (113e259)
34.7 (25.9e43.8)
40.4 (24.9e64.4)
8 (6.9)
51 (44.0)

20 (2.7)
58 (7.9)
247 (33.7)
423 (57.7)
27 (3.7)

8 (1.9)
10 (2.4)
165 (39.7)
203 (48.8)
8 (1.9)

6 (3.0)
20 (10.0)
49 (24.4)
147 (73.1)
17 (8.5)

6 (5.2)
28 (24.1)
33 (28.4)
73 (62.9)
2 (1.7)

(42.2)
(35.3)
(25.9)
(18.1)

Abbreviations: HFNC ¼ high ﬂow nasal cannula; NIPPV ¼ noninvasive positive pressure ventilation; IMV ¼ invasive mechanical
ventilation; ICU ¼ intensive care unit; VTE ¼ venous thromboembolism; BG ¼ blood glucose; CV ¼ coefﬁcient of glucose variation;
DKA ¼ diabetic ketoacidosis.
Numerical data are expressed as mean ± SD or median (IQR). Categorical data are expressed as n (%). No data are missing.
a
Included patients not on oxygen therapy or patients requiring low ﬂow nasal cannula.
b
Included patients requiring HFNC, NIPPV or IMV.
c
Included any combination of the sliding scale insulin aspart, insulin glargine or scheduled (e.g., mealtime) insulin aspart.

even after adjustment for age, gender, comorbidities
and use of other medications such as metformin and
insulin. Previous research22 demonstrated anti-inﬂammatory effects of GLP-1 agonists, especially
during respiratory infections. A study22 on a mouse
model of inﬂuenza H9N2 virus-induced acute lung
injury demonstrated that liraglutide alleviated the
severity of lung injury. Liraglutide did not affect
viral titers in infected lungs, but it decreased levels
of cytokines such as IL-1b, IL-6 and TNF-a in
bronchoalveolar lavage ﬂuid. We did not see a signiﬁcant association with the use of other medications, including insulin (OR, 1.20; 95% CI,
0.84e1.71).
Our analysis highlighted that increasing age, coexisting CKD greater than stage 3, admission to the
ICU and the use of invasive mechanical ventilation
were independent predictors of in-hospital mortality in patients with diabetes. These results are in
agreement with multiple previous studies and systematic reviews.23,24

We also examined inpatient glycemic control and
its association with the outcomes. Patients who died
in the hospital more frequently had less than 50% of
BG in the target range and a CV greater than 36%.
However, after accounting for other factors, these
patients had similar odds of death as patients with
over 50% of BG in target or a CV under 36%. A
potential explanation for this might be that the
impact of glycemic control on mortality was too
small to be detected, when compared to age, CKD or
use of mechanical ventilation. A similar lack of association of inpatient glycemic control, estimated via
mean glucose per patient-day, on illness severity
and mortality has been reported previously.25 On
the other hand, several previous studies6,26,27 have
demonstrated that hyperglycemia was associated
with a higher risk of severe disease and death during COVID-19 admission. However, these studies
had different estimations of hyperglycemia, such as
by using the highest 2 h postprandial BG,26 admission fasting BG27 or the mean BG on days 2e3.6
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Table 3. Univariable and multivariable association of preadmission factors with severe diseasea.
Characteristic

Unadjusted Odds Ratio (95% CI)

P value

Adjusted Odds Ratio (95% CI)

P value

Age (5-year increments)
Male sex vs. female
African American race vs. otherb
Ever smoker
BMI (increments of 5 kg/m2)
HTN
HLD
CADc
CKD stage 3 or higher
CVA or TIA
Chronic lung diseased
Type 2 diabetes vs. type 1
HbA1c (%)
Log days since the last HbA1c
Use of insulin
Use of metformin
Use of sulfonylurea
Use of TZD
Use of DPP-4 inhibitor
Use of GLP-1 agonist
Use of SGLT-2 inhibitor
Outpatient use of steroids

1.03
1.18
0.91
1.27
1.06
0.98
0.82
1.18
1.62
0.75
1.51
1.57
0.98
1.20
1.30
0.63
0.89
0.98
0.92
0.60
0.83
1.08

0.26
0.28
0.54
0.20
0.17
0.94
0.28
0.31
0.012
0.16
0.012
0.46
0.56
0.025
0.08
0.002
0.52
0.97
0.75
0.06
0.57
0.77

1.06
1.33
0.91
1.18
1.13
0.92
0.74
0.94
1.38
0.67
1.49
0.62
0.99
1.25
1.20
0.67
0.90
1.08
0.94
0.49
1.22
0.87

0.10
0.08
0.58
0.40
0.025
0.77
0.16
0.73
0.14
0.07
0.024
0.56
0.84
0.012
0.32
0.025
0.61
0.87
0.82
0.016
0.58
0.64

(0.98e1.08)
(0.88e1.58)
(0.67e1.23)
(0.88e1.82)
(0.97e1.16)
(0.60e1.62)
(0.58e1.17)
(0.86e1.61)
(1.11e2.35)
(0.51e1.12)
(1.10e2.08)
(0.11e2.60)
(0.92e1.05)
(1.02e1.41)
(0.97e1.75)
(0.47e0.84)
(0.61e1.28)
(0.40e2.35)
(0.55e1.51)
(0.34e1.02)
(0.43e1.57)
(0.63e1.84)

(0.99e1.13)
(0.96e1.84)
(0.66e1.26)
(0.80e1.75)
(1.02e1.25)
(0.52e1.62)
(0.49e1.13)
(0.64e1.37)
(0.90e2.12)
(0.44e1.03)
(1.05e2.10)
(0.13e3.07)
(0.92e1.07)
(1.05e1.49)
(0.84e1.71)
(0.47e0.95)
(0.61e1.34)
(0.42e2.76)
(0.55e1.61)
(0.27e0.87)
(0.60e2.46)
(0.50e1.54)

Abbreviations: BMI ¼ body mass index; HTN ¼ hypertension; HLD ¼ hyperlipidemia; CAD ¼ coronary artery disease; CKD ¼ chronic
kidney disease; CVA ¼ cerebrovascular accident; TIA ¼ transient ischemic attack; HbA1c ¼ hemoglobin A1c; TZD ¼ thiazolidinedione;
DPP-4 ¼ dipeptidyl peptidase 4; GLP-1 ¼ glucagon-like peptide 1; SGLT-2 ¼ sodium-glucose cotransporter-2.
a
Based on 733 patients and 317 events. Severe disease was deﬁned as need for high ﬂow nasal cannula, noninvasive positive pressure
ventilation, invasive mechanical ventilation or death during the hospitalization. Univariable and multivariable logistic regression was
performed with preadmission characteristics as covariates. Multiple imputation was used to estimate missing values for BMI, HbA1c and
time since HbA1c.
b
Other includes White, Asian, Hispanic/Latino or unknown.
c
Included patients with stable angina or history of acute coronary syndrome.
d
Included patients with asthma, chronic obstructive pulmonary disease or pulmonary hypertension.

Although not statistically signiﬁcant (OR 1.36; 95%
CI, 1.00e1.84; p ¼ 0.05), a trend was observed with
increasing time since the last HbA1c test and greater
odds of death during hospital stay. As a similar

signal was not observed with the markers of inpatient control, this demonstrates the importance of
outpatient control and overall social determinants of
health with regards to hospital outcomes.

Table 4. Univariable and multivariable logistic regression of factors associated with in-hospital deatha.
Characteristic
Model 1
Age (5-year increment)
CKD greater than stage 3
Log days since the last HbA1c
Admission to ICU
Need for IMV
Admission serum creatinine (mg/dL)
Use of steroids other than DXM
Use of tocilizumab
Use of insulin drip
Model 2
CV greater than 36%
Percentage in target greater than 50%

Unadjusted Odds Ratio (95% CI)

P value

Adjusted Odds Ratio (95% CI)

P value

1.17 (1.09e1.27)
3.32 (2.14e5.12)
1.37 (1.09e1.72)
15.37 (9.72e24.89)
24.42 (15.08e40.32)
1.09 (1.02e1.16)
3.00 (1.93e4.65)
4.48 (2.43e8.15)
6.23 (3.54e10.94)

<0.001
<0.001
0.007
<0.001
<0.001
0.005
<0.001
<0.001
<0.001

1.21
3.38
1.36
2.93
8.67
0.95
1.48
0.99
2.02

<0.001
0.001
0.05
0.011
<0.001
0.41
0.20
0.98
0.07

1.56 (1.04e2.34)
0.62 (0.40e0.93)

0.032
0.023

0.73 (0.42e1.28)
0.80 (0.46e1.37)

(1.09e1.34)
(1.67e6.84)
(1.00e1.84)
(1.28e6.69)
(3.88e19.39)
(0.85e1.07)
(0.81e2.70)
(0.44e2.24)
(0.93e4.40)

0.28
0.41

Abbreviations: CKD ¼ chronic kidney disease; HbA1c ¼ hemoglobin A1c; ICU ¼ intensive care unit; IMV ¼ invasive mechanical
ventilation; DXM ¼ dexamethasone, CV ¼ coefﬁcient of glucose variation.
a
Based on 733 patients and 116 events (in-hospital death). Model 1 included terms with non-zero coefﬁcients from elastic net
regression. Model 2 included all terms from Model 1 with addition of CV and percentage in target range. Rather than treating as
continuous variables, CV and percentage in target range were divided into two groups (36%,>36% and 50%,>50, respectively).
Multiple imputation method was used to estimate missing values for time since HbA1c variable.

Several limitations of this study should be discussed. First, this was a retrospective observational
study. The deﬁnition of clinical conditions and
outpatient medications relied on the accuracy of
hospital EMR and admission medication reconciliation. Second, due to the nature of observational
studies, this study can only detect association, rather
than causality. Third, glucose monitoring was not
continuous. However, the average number of BG
values per patient per day was 5.1, which allowed
enough data for glycemic control assessment.
Fourth, although we collected data on different insulin modalities, we did not collect exact insulin
doses used for each patient. This raises the possibility that the amount of insulin use could have
affected the outcomes. Further prospective studies,
potentially with the use of continuous glucose
monitoring, should be done for a better understanding of the association of glycemic control and
hospital outcomes.
Notwithstanding these limitations, this study
provides a comprehensive evaluation of preadmission characteristics, diabetes management and
inpatient glycemic control. The study also sheds
light on factors predictive of severe disease or death
during admission with acute COVID-19 in a population with underlying diabetes.

5. Conclusions
In a population with underlying diabetes, coexisting obesity, chronic lung disease and longer
time since the last HbA1c were the factors associated with increased odds of severe disease during
the admission with COVID-19. Preadmission use
of metformin or GLP-1 agonists was associated
with decreased odds of severe disease. Older patients, patients with a co-existing chronic kidney
disease, patients admitted to ICU and on mechanical ventilation all had higher odds of in-hospital death.
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